Compassionate and optimum use of new tuberculosis drugs

In our opinion, since the rational use of new drugs (aimed at protecting both the patient and the drug) is an internationally agreed milestone, the simultaneous use of delamanid and bedaquiline might be considered if several conditions are met: an effective treatment cannot be designed by using only...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2015-10, Vol.15 (10), p.1131-1132
Main Authors: Matteelli, Alberto, D'Ambrosio, Lia, Centis, Rosella, Tadolini, Marina, Migliori, Giovanni Battista
Format: Article
Language:English
Subjects:
Antitubercular Agents - therapeutic use
Diarylquinolines - therapeutic use
Drugs
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - surgery
Health Services Accessibility
Humans
Infectious Disease
Infectious diseases
Male
Mycobacterium
Nitroimidazoles - therapeutic use
Oxazoles - therapeutic use
Public health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In our opinion, since the rational use of new drugs (aimed at protecting both the patient and the drug) is an internationally agreed milestone, the simultaneous use of delamanid and bedaquiline might be considered if several conditions are met: an effective treatment cannot be designed by using only one new drug in addition to the optimised background regimen, the clinical centre is qualified, informed consent and pharmacovigilance are in place, and new drug use is supported by expert opinion (panel).
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(15)00296-0